Clover Health Investments (NASDAQ:CLOV - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03, Zacks reports. Clover Health Investments had a negative net margin of 5.92% and a negative return on equity of 25.46%. The business had revenue of $336.96 million for the quarter, compared to the consensus estimate of $347.41 million. Clover Health Investments updated its FY 2025 guidance to EPS.
Clover Health Investments Trading Down 8.3 %
Shares of CLOV stock traded down $0.33 on Monday, hitting $3.64. The stock had a trading volume of 7,506,030 shares, compared to its average volume of 6,195,034. Clover Health Investments has a twelve month low of $0.61 and a twelve month high of $4.87. The company has a fifty day moving average price of $4.04 and a two-hundred day moving average price of $3.60. The firm has a market cap of $1.82 billion, a P/E ratio of -18.20 and a beta of 1.99.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on CLOV shares. Craig Hallum began coverage on Clover Health Investments in a report on Tuesday, December 17th. They set a "buy" rating and a $6.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on Clover Health Investments from $4.20 to $4.50 and gave the stock a "buy" rating in a report on Monday.
Check Out Our Latest Research Report on CLOV
Clover Health Investments Company Profile
(
Get Free Report)
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
Featured Articles
Before you consider Clover Health Investments, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clover Health Investments wasn't on the list.
While Clover Health Investments currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
